LIVZON PHARMA (01513): Tian Qiusheng and Huang Jinhua Resign as Independent Non-Executive Directors

Stock News
2025/10/14

LIVZON PHARMA (01513) announced that the Board of Directors recently received written resignation letters from independent non-executive directors Mr. Tian Qiusheng and Mr. Huang Jinhua. Both Mr. Tian Qiusheng and Mr. Huang Jinhua have served as independent non-executive directors of the company since October 15, 2019, and by October 15, 2025, they will have served continuously as independent non-executive directors for six years. According to the "Administrative Measures for Independent Directors of Listed Companies" and the "Articles of Association," among other relevant regulations, independent directors may not serve for more than six consecutive years. Therefore, Mr. Tian Qiusheng and Mr. Huang Jinhua submitted written resignation letters to the Board of Directors. Mr. Tian Qiusheng has applied to resign from his positions as independent non-executive director of the company's eleventh Board of Directors, member of the Audit Committee, chairman of the Remuneration and Assessment Committee, member of the Nomination Committee, and member of the Environmental, Social and Governance Committee. Mr. Huang Jinhua has applied to resign from his position as member of the Environmental, Social and Governance Committee. To ensure the normal operation of the Board of Directors, before new independent non-executive directors are elected at the company's shareholders' meeting, Mr. Tian Qiusheng and Mr. Huang Jinhua will continue to fulfill their respective responsibilities as independent non-executive directors and members of various specialized committees of the Board of Directors in accordance with the "Articles of Association," "Administrative Measures for Independent Directors of Listed Companies," "Hong Kong Listing Rules," and other relevant regulations.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10